Mark A.  Kronenfeld net worth and biography

Mark Kronenfeld Biography and Net Worth

Director of Pacira BioSciences

Dr. Kronenfeld has served as a director since June 2013. Dr. Kronenfeld has been the Chairman of Anesthesiology at Maimonides Medical Center, a large tertiary care academic medical center in New York City, since January 2022, was the Vice Chairman from March 2009 to January 2022, and has served as Medical Director of Perioperative Services for Maimonides Medical Center since January 2011. Dr. Kronenfeld is the Managing Partner of Anesthesia Associates of Boro Park, a private medical practice in Anesthesiology and Pain Management. Dr. Kronenfeld currently serves on the Board as a member of the Scientific Committee of HBM Healthcare Investments and as a Scientific and Medical Advisor and Board Observer of Nanowear Inc., a private medical device, digital monitoring company. In 2001, Dr. Kronenfeld founded Ridgemark Capital Management (“Ridgemark”), a healthcare-focused hedge fund that invested in public and private healthcare and biomedical companies. He served as the Managing Partner and Portfolio Manager of Ridgemark from April 2001 to December 2008. Dr. Kronenfeld has founded and/or managed various consulting and investment companies focused on healthcare and medical technologies and has served on and chaired multiple leadership committees for various hospitals and medical centers. Previously, Dr. Kronenfeld taught and practiced adult and pediatric cardiac anesthesia at New York University (“NYU”) and was Chief of Cardiac Anesthesiology at Hackensack University Medical Center and was Founder and President of GMS Anesthesia Associates, a private medical practice. Dr. Kronenfeld received his B.A. in Biology from SUNY Buffalo and his M.D. degree and completed his residency in Anesthesiology at the University of California, San Diego School of Medicine, and completed a fellowship in Cardiothoracic Anesthesiology at New York University Medical Center. While an Assistant Professor and Attending Cardiac Anesthesiologist at NYU, Dr. Kronenfeld received and completed a Kellogg-sponsored Fellowship in Heath Care Management for Future Leaders in Health Care at NYU’s Graduate School of Management.

What is Mark A. Kronenfeld's net worth?

The estimated net worth of Mark A. Kronenfeld is at least $429.17 thousand as of June 8th, 2023. Dr. Kronenfeld owns 17,897 shares of Pacira BioSciences stock worth more than $429,170 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Kronenfeld may own. Learn More about Mark A. Kronenfeld's net worth.

How do I contact Mark A. Kronenfeld?

The corporate mailing address for Dr. Kronenfeld and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at [email protected]. Learn More on Mark A. Kronenfeld's contact information.

Has Mark A. Kronenfeld been buying or selling shares of Pacira BioSciences?

Mark A. Kronenfeld has not been actively trading shares of Pacira BioSciences in the last ninety days. Most recently, Mark A. Kronenfeld sold 15,000 shares of the business's stock in a transaction on Thursday, June 8th. The shares were sold at an average price of $37.04, for a transaction totalling $555,600.00. Following the completion of the sale, the director now directly owns 17,897 shares of the company's stock, valued at $662,904.88. Learn More on Mark A. Kronenfeld's trading history.

Who are Pacira BioSciences' active insiders?

Pacira BioSciences' insider roster includes Marcelo Bigal (Director), Mark Froimson (Director), Mark Kronenfeld (Director), Frank Lee (Chief Executive Officer & Director), Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), Jonathan Slonin (Chief Medical Officer), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), Kristen Williams (Chief Administrative Officer & Secretary), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.

Are insiders buying or selling shares of Pacira BioSciences?

In the last twelve months, insiders at the sold shares 6 times. They sold a total of 19,789 shares worth more than $479,312.82. The most recent insider tranaction occured on November, 17th when insider Jonathan Slonin sold 3,960 shares worth more than $95,396.40. Insiders at Pacira BioSciences own 6.4% of the company. Learn More about insider trades at Pacira BioSciences.

Information on this page was last updated on 11/17/2025.

Mark A. Kronenfeld Insider Trading History at Pacira BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2023Sell15,000$37.04$555,600.0017,897View SEC Filing Icon  
3/6/2019Buy1,700$38.97$66,249.009,277View SEC Filing Icon  
8/28/2018Buy1,000$44.61$44,610.008,577View SEC Filing Icon  
11/10/2017Buy1,000$41.60$41,600.006,795View SEC Filing Icon  
6/6/2016Sell900$46.95$42,255.002,950View SEC Filing Icon  
See Full Table

Mark A. Kronenfeld Buying and Selling Activity at Pacira BioSciences

This chart shows Mark A Kronenfeld's buying and selling at Pacira BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pacira BioSciences Company Overview

Pacira BioSciences logo
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Read More

Today's Range

Now: $23.98
Low: $23.90
High: $24.34

50 Day Range

MA: $23.15
Low: $21.01
High: $25.77

2 Week Range

Now: $23.98
Low: $18.17
High: $27.64

Volume

573,725 shs

Average Volume

722,252 shs

Market Capitalization

$1.03 billion

P/E Ratio

53.29

Dividend Yield

N/A

Beta

0.23